VISTAGEN THERAPEUTICS INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
VISTAGEN THERAPEUTICS INC. - More news...
VISTAGEN THERAPEUTICS INC. - More news...
- VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
- VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
- VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
- VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
- VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022
- VistaGen Therapeutics to Present at the Jefferies London Healthcare Conference
- VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update
- VistaGen Therapeutics to Report Fiscal Year 2022 Second Quarter Financial Results and Recent Developments on November 10, 2021
- VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
- VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation of PALISADE-2
- VistaGen Therapeutics to Participate in Baird’s 2021 Global Healthcare Conference
- VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update
- VistaGen Therapeutics to Report Fiscal Year 2022 First Quarter Financial Results and Host Conference Call and Webcast on August 12, 2021
- VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
- VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors
- VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
- VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors
- VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference Call and Webcast June 29, 2021
- VistaGen Therapeutics Set to Join the Russell 2000® Index
- VistaGen Therapeutics, Inc. - VTGN Stock Chart Technical Analysis for 05-20-2021
- Thinking about buying stock in Virgin Galactic, Vistagen Therapeutics, PDS Biotechnology, Super League Gaming, or Allogene Therapeutics?
- VistaGen Therapeutics to Present at Two Investor Conferences in June
- VistaGen Therapeutics Announces Appointment of Ann Cunningham as Chief Commercial Officer
- VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines
- VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
- VistaGen’s PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study
- VistaGen Therapeutics, Inc. - VTGN Stock Chart Technical Analysis for 02-18-2021
- VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
- VistaGen Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
- VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders